Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 70 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Pembrolizumab in addition to chemotherapy for advanced or metastatic urothelial cancer - first line	Pembrolizumab (Keytruda; MK-3475)	Urothelial cancer	Urological Cancer	2018	View \| Download
Pembrolizumab in addition to Chemotherapy for Locally Advanced, Non-Metastatic Triple Negative Breast Cancer – neoadjuvant, first line	Pembrolizumab (Keytruda; MK-3475)	Breast cancer	Breast Cancer	2018	View \| Download
Pembrolizumab in addition to chemotherapy for locally recurrent, inoperable or metastatic triple-negative breast cancer - first line	Pembrolizumab (Keytruda; MK-3475)	Breast cancer	Breast Cancer	2018	View \| Download
Pembrolizumab in addition to chemotherapy for perioperative treatment of gastric or gastro-oesophageal junction adenocarcinoma	FLOT , Pembrolizumab (Keytruda; MK-3475)	Gastric cancer , Gastro-oesophageal junction cancer	Gastrointestinal Cancer	2019	View \| Download
Pembrolizumab in addition to cisplatin and fluorouracil for recurrent locally advanced or metastatic oesophageal cancer – First-line	5-Fluorouracil , Cisplatin (Platinol) , Pembrolizumab (Keytruda; MK-3475)	Oesophageal cancer	Head and Neck Cancer	2019	View \| Download
Pembrolizumab in addition to docetaxel for chemotherapy-naive metastatic castration-resistant prostate cancer – second line	Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Pembrolizumab (Keytruda; MK-3475)	Prostate cancer	Male Reproductive Cancer	2020	View \| Download
Pembrolizumab in addition to lenvatinib for PD-L1 positive (at least 1%) non-small-cell lung cancer – first line	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Pembrolizumab in addition to platinum therapy and radiation for unresectable locally advanced head and neck squamous cell carcinoma	Cisplatin (Platinol) , Pembrolizumab (Keytruda; MK-3475)	Head and neck cancer	Head and Neck Cancer	2019	View \| Download
Pembrolizumab in addition to platinumpemetrexed chemotherapy for metastatic EGRF mutant non-squamous non-small-cell lung cancer – second line	Pembrolizumab (Keytruda; MK-3475) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Pembrolizumab in addition to standard of care chemotherapy for extensive stage small cell lung cancer – first line	Pembrolizumab (Keytruda; MK-3475)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2018	View \| Download